Literature DB >> 33014710

Cavitary pulmonary tuberculosis with COVID-19 coinfection.

Zohaib Yousaf1,2, Adeel A Khan1, Haseeb A Chaudhary3, Kamran Mushtaq2,4, Jabeed Parengal5, Mohamad Aboukamar5, Muhammad Umair Khan2,4, Mouhand F H Mohamed1,2.   

Abstract

The COVID-19 pandemic has strained the healthcare system worldwide, leading to an approach favoring judicious resource allocation. A focus on resource preservation can result in anchoring bias and missed concurrent diagnosis. Coinfection of Mycobacterium tuberculosis (TB) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has implications beyond morbidity at the individual level and can lead to unintended TB exposure to others. We present six cases of COVID-19 with newly diagnosed cavitating pulmonary tuberculosis to highlight the significance of this phenomenon and favorable outcomes if recognized early.
© 2020 The Author(s).

Entities:  

Keywords:  COVID-19; Co-infection; Mycobacterium tuberculosis; Pulmonary tuberculosis; SAR-CoV-2; TB

Year:  2020        PMID: 33014710      PMCID: PMC7521360          DOI: 10.1016/j.idcr.2020.e00973

Source DB:  PubMed          Journal:  IDCases        ISSN: 2214-2509


Background

The modern-day medical practice uses William Osler’s principles of clinical reasoning. “Occam’s razor” advocates a simplistic approach where all symptoms are attributed to a single disease [1]. The counterargument to this diagnostic parsimony is “Hickam's dictum," which favors disease plurality in a single patient. Numerous shortcomings in the current COVID-19 pandemic have skewed our practice in favor of the former principle to preserve resources. This practice has led to anchoring bias and overlooking of other concomitant diseases [2]. Historical evidence suggests higher mortality in patients with concurrent infection of TB and respiratory viruses, such as influenza [3,4]. We present six COVID-19 patients who were co-infected with pulmonary TB with a favorable outcome. All patients had an initial working diagnosis of COVID-19 pneumonia on triage. It was on a detailed review that the probability of pulmonary TB coinfection became apparent leading to isolation from other COVID-19 patients.

Case presentations

Subjects

We performed a retrospective analysis of the six male patients co-infected with TB and COVID-19 (software utilized: Jamovi version 1.1.9, available at www.jamovi.org). Extracted data included baseline demographics, clinical characteristics, laboratory values, imaging, and microbiologic findings.

Patient characteristics

All patients were male owing to the preponderance of male immigrant population in Qatar. The mean age of patients was 35.5 years. All patients were from TB endemic area of south-east Asia. Only one patient had previous diagnosis of diabetes mellitus (DM). Other patients had no previous co-morbidities. The mean duration of symptoms prior to hospitalization was 14 days. Detailed information is shown in Table 1.
Table 1

Patient’s characteristics.

CharacteristicsPatient 1Patient 2Patient 3Patient 4Patient 5Patient 6
Age343250352735
SexMaleMaleMaleMaleMaleMale
NationalityNepaleseNepaleseIndianBangladeshiIndianBangladeshi
Past Medical HistoryNoneNoneDiabetes MellitesNoneNoneNone
Duration of symptoms (days)1082130510
SymptomsFever, productive cough, myalgiasDry cough, fatigue.Dry coughdry cough, feverFever, myalgias, headacheDry cough
B-Type symptomsSubjective weight loss5 % Weight loss over 6 monthsSubjective weight loss5 % weight loss over 3monthsNoneSubjective weight loss
Patient’s characteristics.

Symptomatology and lab results

The most common symptoms were cough (83.3 %), followed by fever (50 %), myalgias (33.3 %), headache (16.6 %) and fatigue (16.6 %). None of our patients reported diarrhea, vomiting, loss of smell, or taste. The main B-type symptom was weight-loss (83.3 %). Lab results included a mean neutrophil count 7.6*103 cells/mm3, lymphocyte count 1.3*103 cells/mm3 and ALT 28.1 U/l. Neutrophil/lymphocyte ratio (NLR) was more than 3.13 in all patients. Screening for hepatitis B, hepatitis C, and human immunodeficiency viruses (HIV) was negative in all patients. All patients had cavitary lesions identified on imaging (Fig. 1, Fig. 2, Fig. 3, Fig. 4, Fig. 5, Fig. 6). Patient 6 also had pleural effusion which turned out to be lymphocytic exudative with a positive nucleic acid amplification test for TB (Fig. 1e).
Fig. 1

Bilateral infiltrates with multiple cavitary lesions.

Fig. 2

Predominantly right middle zone infiltrates with multiple cavitary lesions.

Fig. 3

Bilateral infiltrates with extensive involvement on right side with multiple cavitary lesions.

Fig. 4

Bilateral infiltrates, more prominent in right upper zone with multiple cavitary lesions.

Fig. 5

Bilateral infiltrates with multiple cavitary lesion.

Fig. 6

Bilateral infiltrates with left middle zone cavitary lesion and left sided pleural effusion.

Bilateral infiltrates with multiple cavitary lesions. Predominantly right middle zone infiltrates with multiple cavitary lesions. Bilateral infiltrates with extensive involvement on right side with multiple cavitary lesions. Bilateral infiltrates, more prominent in right upper zone with multiple cavitary lesions. Bilateral infiltrates with multiple cavitary lesion. Bilateral infiltrates with left middle zone cavitary lesion and left sided pleural effusion.

Diagnosis

The diagnosis of pulmonary TB in patients 1–6 was initially based on a positive sputum smear for acid-fast bacilli (AFB). Later, the TB culture from sputum sample turned out to be positive in all patients. All patients were smear-negative by 6 weeks of treatment with median of 3 weeks (Table 2).
Table 2

Diagnosis.

Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6
IGRA for TBNegativeIndeterminateIndeterminateIndeterminatePositivePositive
AFB smear statusPositive from sputumPositive from sputumPositive from sputumPositive from sputumPositive from sputumPositive from sputum
AFB culture statusPositive from sputumPositive from sputumPositive from sputumPositive from sputumPositive from sputumPositive from sputum
TB DiagnosisPulmonary TBPulmonary TBPulmonary TBPulmonary TBPulmonary TBPulmonary and pleural TB
SARS-CoV-2 RT-PCR (Nasopharyngeal Swab)PositivePositivePositivePositivePositivePositive
Number of days for negative SARS-CoV-2 RT-PCR424214722821
Number of days for negative AFB smear/TB PCR421428212114
New Diagnosis during hospitalizationPre-DiabetesDiabetes MellitesAnemiaPre-diabetesAnemiaNone

(IGRA: Interferon Gamma Release Assay, AFB: Acid Fast Bacillus, TB: Tuberculosis, SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2, RT-PCR: Reverse Transcriptase-Polymerase Chain Reaction).

Diagnosis. (IGRA: Interferon Gamma Release Assay, AFB: Acid Fast Bacillus, TB: Tuberculosis, SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2, RT-PCR: Reverse Transcriptase-Polymerase Chain Reaction). All patients tested positive for SARS-CoV-2 RNA by RT-PCR of the nasopharyngeal swab. Follow-up COVID-19 oropharyngeal and nasopharyngeal swabs were initially repeated two weeks from diagnosis and then weekly until negative. The clearance of virus was variable, but two patients had positive SARS-CoV-2 RT-PCR beyond four weeks (Table 2).

Treatment

All patients received five days of Ceftriaxone, Azithromycin, and Hydroxychloroquine for COVID-19 pneumonia, according to the local COVID-19 management guidelines at that time. All patients also received first-line anti-tuberculous therapy (ATT) consisting of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol with Pyridoxine.

Prognosis and outcome

All patients admitted from the emergency improved with treatment and were discharged in a stable condition from the hospital.

Discussion

There is a paucity of data reported on TB and SARS-CoV-2 coinfection, which is likely due to under-reporting. However, missed diagnosis, early mortality, and limited testing facilities for SARS-CoV-2 may also be responsible [5]. None of our patients had a known history of direct exposure to TB; however, all of them belonged to areas where TB is endemic i.e. South-Asian descent. The exact mechanism underlying COVID-19 and TB coinfection is unknown. An interplay of various interleukins (IL) triggered by inflammatory response to viral infection that affect T-cell Immune response is an argument found in the literature [6]. Type-I interferon (IFN) has antiviral properties, but detrimental effects of inappropriate or mistimed type-I IFN response in viral infections also exist that may promote susceptibility to TB infection [7]. Other factors, such as dysregulated glucose metabolism, predispose patients to an excessive uncontrolled inflammatory response, which leads to a higher risk of developing COVID-19 pneumonia and rapid disease progression [8]. Additionally, DM also increases the risk of developing active tuberculosis infection by two to four folds [9]. Only one of our patients had established diagnosis of DM. However, 66.6 % of our patients had impaired glucose metabolism with an average HbA1c of 6.48. It is also important to note that a population with low socioeconomic status may carry a higher risk of exposure and disease spread [10,11], as seen in our case series. In terms of risk stratification, Ai-Ping Yang et al. have studied neutrophil to lymphocyte ratio (NLR) and age as an independent biomarker for poor clinical outcome in COVID-19 patients [12]. All our patients had an NLR greater than 3.3 with a mean ferritin level of 1686 ug/L and CRP 98.7 mg/L denoting at least moderate disease severity in an otherwise healthy young population (Table 2). The limitation to interpreting these parameters is coinfection with TB that makes it difficult to assess COVID-19 related disease severity. Detecting patients with this coinfection has implications for patient management. Cohorting COVID-19 patients with patients who have undiagnosed MTB may lead to its nosocomial transmission. COVID-19 patients with pulmonary TB coinfection will require airborne isolation, even if they do not receive invasive or non-invasive mechanical ventilation. This may affect the length of stay and pose a challenge in a limited resource setting.

Conclusion

Coinfection with COVID-19 and Mycobacterium tuberculosis may alter disease course and management. A high index of suspicion is required for detection of this coinfection especially in population at high risk for TB or belonging to endemic areas. Coinfection may not correlate with worse outcomes if recognized early.

Author contributions

The first three authors contributed equally to this article. ZY conceived the topic idea, identified the cases, and managed some of the cases. Additionally, he performed the initial literature review, data analysis, and wrote the initial manuscript. AAK assisted in the literature review and wrote up the manuscript. HAC critically reviewed and revised the final manuscript. KM, MUK and MFHM assisted in analyzing the cases and critically revising the manuscript. JB and SAK were involved in managing the cases and reviewed the data as infectious disease experts. All authors approved the final version for submission. Consent Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

CRediT authorship contribution statement

Zohaib Yousaf: Conceptualization, Methodology, Project administration, Writing - original draft. Adeel A. Khan: Writing - original draft. Haseeb A. Chaudhary: Writing - review & editing. Kamran Mushtaq: Writing - review & editing. Jabeed Parengal: Supervision. Mohamad Aboukamar: Supervision. Muhammad Umair Khan: Project administration. Mouhand F.H. Mohamed: Writing - review & editing.

Declaration of Competing Interest

The authors declare no conflict of interest.
  4 in total

1.  An argument against the use of Occam's razor in modern medical education.

Authors:  Martin B Whyte
Journal:  Med Teach       Date:  2017-04-10       Impact factor: 3.650

2.  Covid-19: Two thirds of healthcare workers who have died were from ethnic minorities.

Authors:  Abi Rimmer
Journal:  BMJ       Date:  2020-04-23

3.  Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010-2011.

Authors:  Sibongile Walaza; Stefano Tempia; Halima Dawood; Ebrahim Variava; Jocelyn Moyes; Adam L Cohen; Nicole Wolter; Michelle Groome; Claire von Mollendorf; Kathleen Kahn; Marthi Pretorius; Marietjie Venter; Shabir A Madhi; Cheryl Cohen
Journal:  BMC Infect Dis       Date:  2015-01-27       Impact factor: 3.090

4.  Diabetes is a risk factor for the progression and prognosis of COVID-19.

Authors:  Weina Guo; Mingyue Li; Yalan Dong; Haifeng Zhou; Zili Zhang; Chunxia Tian; Renjie Qin; Haijun Wang; Yin Shen; Keye Du; Lei Zhao; Heng Fan; Shanshan Luo; Desheng Hu
Journal:  Diabetes Metab Res Rev       Date:  2020-03-31       Impact factor: 4.876

  4 in total
  15 in total

1.  From Hume to Wuhan: An Epistemological Journey on the Problem of Induction in COVID-19 Machine Learning Models and its Impact Upon Medical Research.

Authors:  Carlos Vega
Journal:  IEEE Access       Date:  2021-07-06       Impact factor: 3.367

Review 2.  Pathogenesis of SARS-CoV-2 and Mycobacterium tuberculosis Coinfection.

Authors:  Taif Shah; Zahir Shah; Nafeesa Yasmeen; Zulqarnain Baloch; Xueshan Xia
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

3.  COVID-19 Associated Imported Plasmodium vivax Malaria Relapse: First Reported Case and Literature Review.

Authors:  Zubair Shahid; Nadia Karim; Fakhar Shahid; Zohaib Yousaf
Journal:  Res Rep Trop Med       Date:  2021-05-10

4.  Pulmonary cavitation: an under-recognized late complication of severe COVID-19 lung disease.

Authors:  Zaid Zoumot; Maria-Fernanda Bonilla; Ali S Wahla; Irfan Shafiq; Mateen Uzbeck; Rania M El-Lababidi; Fadi Hamed; Mohamed Abuzakouk; Mahmoud ElKaissi
Journal:  BMC Pulm Med       Date:  2021-01-12       Impact factor: 3.317

Review 5.  Increased antimicrobial resistance during the COVID-19 pandemic.

Authors:  Chih-Cheng Lai; Shey-Ying Chen; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2021-03-19       Impact factor: 5.283

6.  Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry.

Authors:  Nathan Wlodarchak; John B Feltenberger; Zhengqing Ye; Jeffrey Beczkiewicz; Rebecca Procknow; Gang Yan; Troy M King; Jennifer E Golden; Rob Striker
Journal:  ACS Med Chem Lett       Date:  2021-01-13       Impact factor: 4.345

7.  Large Cavitary Lung Lesions in a Patient with Severe COVID-19 Pneumonia.

Authors:  Sergey Avdeev; Galia Nuralieva; Galina Nekludova
Journal:  Am J Trop Med Hyg       Date:  2021-10-20       Impact factor: 3.707

8.  Study to assess aetiology, clinical and imaging characteristics of post Covid-19 pulmonary cavitation.

Authors:  Deependra Kumar Rai; Rajeev K Priyadarshi; Saurabh Karmaker
Journal:  J Family Med Prim Care       Date:  2022-02-16

Review 9.  Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review.

Authors:  Narjess Bostanghadiri; Faramarz Masjedian Jazi; Shabnam Razavi; Lanfranco Fattorini; Davood Darban-Sarokhalil
Journal:  Front Microbiol       Date:  2022-02-03       Impact factor: 5.640

10.  Development of cavitary lung disease as a long-term complication of coronavirus disease 2019 in a young previously healthy patient: a case report.

Authors:  Goar Egoryan; Elise Hyser; Ammar H Mushtaq; Maria Adriana Yanez-Bello; Daniela Patricia Trelles-Garcia; Harvey J Friedman; Guillermo Rodriguez-Nava
Journal:  J Med Case Rep       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.